Back
Protalix Biotherapeutics, Inc. 10K Form
Sell
30
PLX
Protalix Biotherapeutics, Inc.
Last Price:
$2.14
Seasonality Move:
7.54%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive PLX News And Ratings
See the #1 stock for the next 7 days that we like better than PLX
PLX Financial Statistics
Sales & Book Value
| Annual Sales: | $52.7M |
|---|---|
| Cash Flow: | $1.6M |
| Price / Cash Flow: | 19.31 |
| Annual Sales: | $0.60 |
| Price / Book: | 3.59 |
Profitability
| EPS (TTM): | -0.08450 |
|---|---|
| Net Income (TTM): | $-6.6M |
| Gross Margin: | $25.2M |
| Return on Equity: | -13.79% |
| Return on Assets: | -8.46% |
Protalix Biotherapeutics, Inc. Earnings Forecast
Key Protalix Biotherapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 28 years for PLX is 47.85%.
-
The Selling, General & Administrative Expenses for PLX have been equal to 22.15% of Gross Profit Margin.
-
The Research & Development expenses have been 36.13% of Revenue.
-
The Net Earning history of PLX is -12.52% of Total Revenues.
-
Per Share Earnings over the last 30 years have been positive in 13 years.
Protalix Biotherapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYAM |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | PLX |
| CUSIP: | 74365A |
| Website: | protalix.com |
Debt
| Debt-to-Equity Ratio: | 0.17 |
|---|---|
| Current Ratio: | 2.51 |
| Quick Ratio: | 1.5 |
Price-to-Earnings
| Trailing P/E Ratio: | 76.23 |
|---|---|
| Forward P/E Ratio: | 0 |
PLX Technical Analysis vs Fundamental Analysis
Sell
30
Protalix Biotherapeutics, Inc. (PLX)
is a Sell
Is Protalix Biotherapeutics, Inc. a Buy or a Sell?
-
Protalix Biotherapeutics, Inc. stock is rated a SellThe current Protalix Biotherapeutics, Inc. [PLX] share price is $2.15. The Score for PLX is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.